3
Meta-analysis of prospective cohort studies of cigarette smoking and the incidence of colon and
rectal cancers
Méta-analyse d’études de cohortes prospectives sur la consommation de tabac et l’incidence des cancers
du côlon et du rectum
Cheng J et al., Eur J Cancer Prev. Avril 2014
Although the American College of Gastroenterology colorectal cancer screening guidelines highlight cigarette
smoking as a risk factor, cigarette smoking is still an arguably underappreciated risk factor for this disease,
especially for its subsites: colon cancer (CC) and rectal cancer (RC). A literature search of MEDLINE and
EMBASE was performed up to 30 April 2013 for prospective cohort studies. A random-effects meta-analysis
was carried out to estimate the summary relative risks (SRRs) and 95% confidence intervals (CIs) for the
associations. A total of 24 prospective studies, which reported data for cigarette smoking and incidence of CC
and RC separately, were included. Our analysis showed that, compared with never-smokers, current smokers had
a higher risk of RC than CC (CC: SRR=1.09, 95% CI, 1.01-1.18; RC: SRR=1.24, 95% CI, 1.16-1.39; PRC vs.
CC=0.034), whereas former smokers had a similar risk of CC and RC. Current smokers had a significantly
higher risk of proximal CC than distal CC (P=0.035). This meta-analysis suggests that cigarette smoking is
associated with an increased risk of both CC and RC, and that the magnitude of the association is stronger for
RC than that for CC.
Occupational asbestos exposure and lung cancer--a systematic review of the literature.
Exposition professionnelle à l'amiante et cancer du poumon - une revue systématique de la littérature.
Nielsen LS et al., Arch Environ Occup Health. Juin 2014
The objective of this study was to evaluate the scientific literature concerning asbestos and lung cancer,
emphasizing low-level exposure. A literature search in PubMed and Embase resulted in 5,864 citations.
Information from included studies was extracted using SIGN. Twenty-one statements were evidence graded. The
results show that histology and location are not helpful in differentiating asbestos-related lung cancer. Pleural
plaques, asbestos bodies, or asbestos fibers are useful as markers of asbestos exposure. The interaction between
asbestos and smoking regarding lung cancer risk is between additive and multiplicative. The findings indicate
that the association between asbestos exposure and lung cancer risk is basically linear, but may level off at very
high exposures. The relative risk for lung cancer increases between 1% and 4% per fiber-year (f-y)/mL,
corresponding to a doubling of risk at 25-100 f-y/mL. However, one high-quality case-control study showed a
doubling at 4 f-y/mL.
Mobile phone use and brain tumours in the CERENAT case-control study.
Utilisation du téléphone portable et tumeurs cérébrales dans l'étude cas-témoins CERENAT.
Coureau G et al., Occup Environ Med. Juillet 2014
The carcinogenic effect of radiofrequency electromagnetic fields in humans remains controversial. However, it
has been suggested that they could be involved in the aetiology of some types of brain tumours.
OBJECTIVES: The objective was to analyse the association between mobile phone exposure and primary
central nervous system tumours (gliomas and meningiomas) in adults.
METHODS: CERENAT is a multicenter case-control study carried out in four areas in France in 2004-2006.
Data about mobile phone use were collected through a detailed questionnaire delivered in a face-to-face manner.
Conditional logistic regression for matched sets was used to estimate adjusted ORs and 95% CIs.
RESULTS: A total of 253 gliomas, 194 meningiomas and 892 matched controls selected from the local electoral
rolls were analysed. No association with brain tumours was observed when comparing regular mobile phone
users with non-users (OR=1.24; 95% CI 0.86 to 1.77 for gliomas, OR=0.90; 95% CI 0.61 to 1.34 for
meningiomas). However, the positive association was statistically significant in the heaviest users when
considering life-long cumulative duration (≥896 h, OR=2.89; 95% CI 1.41 to 5.93 for gliomas; OR=2.57; 95%